Fourteen consecutive clinically definite relapsing-remitting multiple sclerosis (MS) patients were treated with monthly intravenous cyclophosphamide (CTX) for 6 months. All had experienced severe clinical deterioration during the 12 months prior to treatment with CTX despite treatment with conventional immunomodulating agents and intravenous methylprednisolone. Treatment with CTX led to improvement and neurologic stability within 6 months which was sustained for at least 18 months after the onset of treatment with CTX. Therapy with CTX was well tolerated. CTX may be of benefit in MS patients who experience rapid clinical worsening and are resistant to conventional therapy.
The IFNB Multiple Sclerosis Study Group I. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology43: 655-661 .
2.
Jacobs LDet al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol39: 285-294 .
3.
Johnson KPet al. (1995) Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial . Neurology45: 1268-1276 .
4.
PRISMS Study Group . (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis . Lancet352: 1498-1504 .
5.
European Study Group on Interferon beta-1b in secondary progressive MS. (1998) Placebo-controlled, multi-center randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis . Lancet352: 1491-1497 .
6.
SPECTRIMS Study Group . (2000) Neurology54 (Suppl 3): A233-A233 (abstract).
7.
Weinstock-Guttman Bet al. (1997) Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide . The Neurologists3: 178-185 .
8.
Gobbini MIet al. (1999) Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis . J Neuroimmunol99: 142-149 .
9.
Kovarsky J. (1983) Clinical Pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic disease . Semin Arthritis Rheum12: 359-372 .
10.
Hauser SLet al. (1983) Intensive immunosuppression in progressive multiple sclerosis: A randomized, three-arm study of high dose cyclophosphamide, plasma exchange, and ACTH . N Eng J Med308: 173-180 .
11.
The Canadian Cooperative Multiple Sclerosis Study Group . (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis . Lancet337: 441-446 .
12.
Likosky WHet al. (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study . J Neurol Neurosurg Psych54: 1055-1060 .
13.
Weiner HLet al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group . Neurology43: 910-918 .
14.
Poser CMet al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol13: 227-231 .
15.
Lublin FD , Reingold SC. (1996) Defining the clinical course of multiple sclerosis: Results of an international survey . Neurology46: 907-911 .
16.
Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) . Neurology33: 1444-1452 .
17.
Wingerchuck DM , Weinshenker BG. (1999) The natural history of multiple sclerosis: implications for trial design . Curr Opin Neurol3: 345-349 .
18.
Bergamaschi Ret al. (1993) Clinical trial in multiple sclerosis: a critical review (1970-1990) . Acta Neurol (Napoli)6: 462-474 .
19.
Balashov KEet al. (1997) Increased IL-12 production in progressive multiple sclerosis: Induction by activated CD4+ cells via CD40 ligand . Proc Natl Acad Sci USA94: 599-603 .
20.
Smith DRet al. (1997) Immune deviation following cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased IL-4 and associated eosinophilia . Ann Neurol42: 313-318 .
21.
Cornabella Met al. (1998) Elevated interleuken-12 in progressive multiple sclerosis correlates with disease activity and is normalized with cyclophosphamide therapy . J Clin Invest102: 671-678 .
22.
Karp C. (1999) Interleukin-12: Amiss in MS . Ann Neurol45: 689-692 .
23.
Hohol MJet al. (1999) Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease . Multiple Sclerosis5: 403-409 .
24.
Edan Get al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multi-center study of active disease using MRI and clinical criteria . J Neurol Neurosurg Psych62: 112-118 .
